G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 36c, Reiterates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GTHX Hot Sheet
Join SI Premium – FREE
G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q2 EPS of $0.14, $0.36 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $42.4 million versus the consensus estimate of $28.95 million.
G1 today reiterated its full year 2023 net revenue guidance. The Company expects to generate between $50 million and $60 million in COSELA net revenue in 2023
For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Citizens Starts Blackstone Secured Lending Fund (BXSL) at Market Perform
- IndeRes Upgrades Nokia OYJ (NOKIA:FH) (NOK) to Reduce (3)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
